{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T21:03:37Z","timestamp":1790283817260,"version":"4.1.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,21]],"date-time":"2021-08-21T00:00:00Z","timestamp":1629504000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,21]],"date-time":"2021-08-21T00:00:00Z","timestamp":1629504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Scientific Foundation of China","award":["81270109, 91539104"],"award-info":[{"award-number":["81270109, 91539104"]}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2019A1515011421"],"award-info":[{"award-number":["2019A1515011421"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Natural Scientific Foundation of Shenzhen","award":["JCYJ20190808122207499"],"award-info":[{"award-number":["JCYJ20190808122207499"]}]},{"name":"Shenzhen Municipal Commission of Science and Technology Innovation","award":["ZDSYS20190902093401689"],"award-info":[{"award-number":["ZDSYS20190902093401689"]}]},{"name":"Shenzhen University General Hospital","award":["SUGH2018QD048"],"award-info":[{"award-number":["SUGH2018QD048"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cardiomyocyte metabolism changes before cardiac remodeling, but its role in early cardiac hypertrophy detection\u00a0remains unclear. This study investigated early changes in plasma metabolomics in a pressure-overload cardiac hypertrophy model induced by transverse aortic constriction (TAC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The TAC model was constructed by partly ligating the aortic arch. Twelve Sprague\u2013Dawley rats were randomly divided into the TAC group (n\u2009=\u20096) and sham group (n\u2009=\u20096). Three weeks after surgery, cardiac echocardiography was performed to assess cardiac remodeling and function. Hematoxylin\/eosin (HE), Masson, and wheat germ agglutinin (WGA) stains were used to observe pathological changes. Plasma metabolites were detected by UPLC-QTOFMS and Q-TOFMS. Specific metabolites were screened by orthogonal partial least squares discriminant analysis (OPLS-DA). Metabolic pathways were characterized by Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis, and the predictive value of the screened metabolites was analyzed by receiver operating characteristic (ROC) curve analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Three weeks after surgery, the TAC and sham groups had similar left heart function and interventricular septum and diastolic left ventricular posterior wall thicknesses. However, on pathological examination, the cross-sectional area of cardiomyocytes and myocardial fibrosis severity were significantly elevated in TAC rats. OPLS-DA showed different metabolic patterns between the TAC and sham groups. Based on the criteria VIP\u2009&gt;\u20091 and P\u2009&lt;\u20090.05, 13 metabolites were screened out. KEGG analysis identified disrupted lysine degradation through the related metabolites 5-aminopentanoic acid, N6-acetyl-\n                      <jats:sc>l<\/jats:sc>\n                      -lysine, and\n                      <jats:sc>l<\/jats:sc>\n                      -lysine, with areas under the ROC curve (AUCs) of 0.917, 0.889, and 0.806, respectively, for predicting compensated cardiomyocyte hypertrophy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Disruption of lysine degradation might be involved in early cardiac hypertrophy development, and related metabolites might be potential predictive and interventional targets for subclinical cardiomyocyte hypertrophy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12872-021-02209-w","type":"journal-article","created":{"date-parts":[[2021,8,21]],"date-time":"2021-08-21T06:02:56Z","timestamp":1629525776000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Abnormalities in lysine degradation are involved in early cardiomyocyte hypertrophy development in pressure-overloaded rats"],"prefix":"10.1186","volume":"21","author":[{"given":"Jialing","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junhao","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanlan","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0590-7627","authenticated-orcid":false,"given":"Xiaojing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,21]]},"reference":[{"key":"2209_CR1","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.yjmcc.2016.06.001","volume":"97","author":"I Shimizu","year":"2016","unstructured":"Shimizu I, Minamino T. Physiological and pathological cardiac hypertrophy. J Mol Cell Cardiol. 2016;97:245\u201362.","journal-title":"J Mol Cell Cardiol"},{"key":"2209_CR2","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41569-018-0007-y","volume":"15","author":"M Nakamura","year":"2018","unstructured":"Nakamura M, Sadoshima J. Mechanisms of physiological and pathological cardiac hypertrophy. Nat Rev Cardiol. 2018;15:387\u2013407.","journal-title":"Nat Rev Cardiol"},{"key":"2209_CR3","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1038\/nrcardio.2016.25","volume":"13","author":"B Ziaeian","year":"2016","unstructured":"Ziaeian B, Fonarow GC. Epidemiology and aetiology of heart failure. Nat Rev Cardiol. 2016;13:368\u201378.","journal-title":"Nat Rev Cardiol"},{"key":"2209_CR4","doi-asserted-by":"publisher","first-page":"4435","DOI":"10.1038\/s41467-018-06639-7","volume":"9","author":"S Nomura","year":"2018","unstructured":"Nomura S, Satoh M, Fujita T, et al. Cardiomyocyte gene programs encoding morphological and functional signatures in cardiac hypertrophy and failure. Nat Commun. 2018;9:4435.","journal-title":"Nat Commun"},{"key":"2209_CR5","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1002\/ehf2.12555","volume":"6","author":"D Tomasoni","year":"2019","unstructured":"Tomasoni D, Adamo M, Lombardi CM, et al. Highlights in heart failure. ESC Heart Fail. 2019;6:1105\u201327.","journal-title":"ESC Heart Fail"},{"key":"2209_CR6","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.cjca.2017.03.009","volume":"33","author":"KA De Jong","year":"2017","unstructured":"De Jong KA, Lopaschuk GD. Complex energy metabolic changes in heart failure with preserved ejection fraction and heart failure with reduced ejection fraction. Can J Cardiol. 2017;33:860\u201371.","journal-title":"Can J Cardiol"},{"key":"2209_CR7","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1161\/CIRCULATIONAHA.107.702795","volume":"116","author":"H Ashrafian","year":"2007","unstructured":"Ashrafian H, Frenneaux MP, Opie LH. Metabolic mechanisms in heart failure. Circulation. 2007;116:434\u201348.","journal-title":"Circulation"},{"key":"2209_CR8","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1161\/CIRCHEARTFAILURE.114.001469","volume":"7","author":"L Lai","year":"2014","unstructured":"Lai L, Leone TC, Keller MP, et al. Energy metabolic reprogramming in the hypertrophied and early stage failing heart: a multisystems approach. Circ Heart Fail. 2014;7:1022\u201331.","journal-title":"Circ Heart Fail"},{"key":"2209_CR9","doi-asserted-by":"publisher","first-page":"H422","DOI":"10.1152\/ajpheart.00219.2020","volume":"319","author":"M Schnelle","year":"2020","unstructured":"Schnelle M, Chong M, Zoccarato A, et al. In vivo [U-13C]glucose labeling to assess heart metabolism in murine models of pressure and volume overload. Am J Physiol Heart Circ Physiol. 2020;319:H422\u201331.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2209_CR10","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1093\/cvr\/cvz045","volume":"115","author":"KL Ho","year":"2019","unstructured":"Ho KL, Zhang L, Wagg C, et al. Increased ketone body oxidation provides additional energy for the failing heart without improving cardiac efficiency. Cardiovasc Res. 2019;115:1606\u201316.","journal-title":"Cardiovasc Res"},{"key":"2209_CR11","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1536\/ihj.18-114","volume":"60","author":"K Nakatani","year":"2019","unstructured":"Nakatani K, Masuda D, Kobayashi T, et al. Pressure overload impairs cardiac function in long-chain fatty acid transporter CD36-knockout mice. Int Heart J. 2019;60:159\u201367.","journal-title":"Int Heart J"},{"key":"2209_CR12","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1161\/CIRCRESAHA.112.277392","volume":"111","author":"JC Chatham","year":"2012","unstructured":"Chatham JC, Young ME. Metabolic remodeling in the hypertrophic heart: fuel for thought. Circ Res. 2012;111:666\u20138.","journal-title":"Circ Res"},{"key":"2209_CR13","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1161\/CIRCRESAHA.118.312017","volume":"123","author":"AA Gibb","year":"2018","unstructured":"Gibb AA, Hill BG. Metabolic coordination of physiological and pathological cardiac remodeling. Circ Res. 2018;123:107\u201328.","journal-title":"Circ Res"},{"issue":"6","key":"2209_CR14","doi-asserted-by":"publisher","first-page":"e008145","DOI":"10.1161\/JAHA.117.008145","volume":"7","author":"A Kimura","year":"2018","unstructured":"Kimura A, Ishida Y, Furuta M, et al. Protective roles of interferon-\u0101\u03b3 in cardiac hypertrophy induced by sustained pressure overload. J Am Heart Assoc. 2018;7(6):e008145.","journal-title":"J Am Heart Assoc"},{"key":"2209_CR15","doi-asserted-by":"publisher","first-page":"e1054","DOI":"10.1161\/CIR.0000000000000490","volume":"135","author":"SL Chow","year":"2017","unstructured":"Chow SL, Maisel AS, Anand I, et al. Role of biomarkers for the prevention, assessment, and management of heart failure: a scientific statement from the American Heart Association. Circulation. 2017;135:e1054\u201391.","journal-title":"Circulation"},{"key":"2209_CR16","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.yexcr.2017.03.052","volume":"360","author":"T Tuomainen","year":"2017","unstructured":"Tuomainen T, Tavi P. The role of cardiac energy metabolism in cardiac hypertrophy and failure. Exp Cell Res. 2017;360:12\u20138.","journal-title":"Exp Cell Res"},{"key":"2209_CR17","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1007\/s00204-015-1477-x","volume":"89","author":"YK Tham","year":"2015","unstructured":"Tham YK, Bernardo BC, Ooi JY, et al. Pathophysiology of cardiac hypertrophy and heart failure: signaling pathways and novel therapeutic targets. Arch Toxicol. 2015;89:1401\u201338.","journal-title":"Arch Toxicol"},{"issue":"4","key":"2209_CR18","doi-asserted-by":"publisher","first-page":"e010926","DOI":"10.1161\/JAHA.118.010926","volume":"8","author":"J Li","year":"2019","unstructured":"Li J, Kemp BA, Howell NL, et al. Metabolic changes in spontaneously hypertensive rat hearts precede cardiac dysfunction and left ventricular hypertrophy. J Am Heart Assoc. 2019;8(4):e010926.","journal-title":"J Am Heart Assoc"},{"key":"2209_CR19","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1161\/CIRCHEARTFAILURE.114.001151","volume":"7","author":"BE Sansbury","year":"2014","unstructured":"Sansbury BE, DeMartino AM, Xie Z, et al. Metabolomic analysis of pressure-overloaded and infarcted mouse hearts. Circ Heart Fail. 2014;7:634\u201342.","journal-title":"Circ Heart Fail"},{"key":"2209_CR20","first-page":"71","volume":"9","author":"P F\u00fcrst","year":"1993","unstructured":"F\u00fcrst P. Dietary l-lysine supplementation: A promising nutritional tool in the prophylaxis and treatment of osteoporosis. Nutrition. 1993;9:71\u20132.","journal-title":"Nutrition"},{"key":"2209_CR21","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1681\/ASN.2013090967","volume":"25","author":"A Shimomura","year":"2014","unstructured":"Shimomura A, Matsui I, Hamano T, et al. Dietary l-lysine prevents arterial calcification in adenine-induced uremic rats. J Am Soc Nephrol. 2014;25:1954\u201365.","journal-title":"J Am Soc Nephrol"},{"key":"2209_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jprot.2012.05.041","volume":"77","author":"K Kotlo","year":"2012","unstructured":"Kotlo K, Johnson KR, Grillon JM, et al. Phosphoprotein abundance changes in hypertensive cardiac remodeling. J Proteomics. 2012;77:1\u201313.","journal-title":"J Proteomics"},{"key":"2209_CR23","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1111\/j.1752-8062.2009.00141.x","volume":"2","author":"MB Calalb","year":"2009","unstructured":"Calalb MB, McKinsey TA, Newkirk S, et al. Increased phosphorylation-dependent nuclear export of class II histone deacetylases in failing human heart. Clin Transl Sci. 2009;2:325\u201332.","journal-title":"Clin Transl Sci"},{"key":"2209_CR24","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/j.jacbts.2019.05.011","volume":"4","author":"CF Liu","year":"2019","unstructured":"Liu CF, Tang WHW. Epigenetics in cardiac hypertrophy and heart failure. JACC Basic Transl Sci. 2019;4:976\u201393.","journal-title":"JACC Basic Transl Sci"},{"key":"2209_CR25","doi-asserted-by":"publisher","first-page":"7163","DOI":"10.1111\/jcmm.14650","volume":"23","author":"J Wan","year":"2019","unstructured":"Wan J, Liu H, Chu J, et al. Functions and mechanisms of lysine crotonylation. J Cell Mol Med. 2019;23:7163\u20139.","journal-title":"J Cell Mol Med"},{"key":"2209_CR26","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/s41569-019-0235-9","volume":"17","author":"P Li","year":"2020","unstructured":"Li P, Ge J, Li H. Lysine acetyltransferases and lysine deacetylases as targets for cardiovascular disease. Nat Rev Cardiol. 2020;17:96\u2013115.","journal-title":"Nat Rev Cardiol"},{"key":"2209_CR27","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-020-09959-3","author":"H Lei","year":"2020","unstructured":"Lei H, Hu J, Sun K, Xu D. The role and molecular mechanism of epigenetics in cardiac hypertrophy. Heart Fail Rev. 2020. https:\/\/doi.org\/10.1007\/s10741-020-09959-3.","journal-title":"Heart Fail Rev"},{"key":"2209_CR28","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/s41580-019-0108-4","volume":"20","author":"MM Rinschen","year":"2019","unstructured":"Rinschen MM, Ivanisevic J, Giera M, et al. Identification of bioactive metabolites using activity metabolomics. Nat Rev Mol Cell Biol. 2019;20:353\u201367.","journal-title":"Nat Rev Mol Cell Biol"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-021-02209-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-021-02209-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-021-02209-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,21]],"date-time":"2021-08-21T06:05:55Z","timestamp":1629525955000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-021-02209-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,21]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2209"],"URL":"https:\/\/doi.org\/10.1186\/s12872-021-02209-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-485000\/v1","asserted-by":"object"}]},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,21]]},"assertion":[{"value":"19 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Ethics Committee of Animal Welfare at the Medical Centers of Chongqing Medical University (Chongqing, China) and Shenzhen University General Hospital (Guangdong, China). All animal experiments complied with the\u00a0ARRIVE guidelines\u00a0and were carried out in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals (NIH Publications No. 8023, revised 1978).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"403"}}